Cohere announced the acquisition of Reliant AI, expanding its sovereign AI strategy and deepening its presence in the global healthcare and life sciences sectors. The deal brings Reliant AI’s research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise AI platform, strengthening the company’s offerings for highly regulated industries where security, privacy, and compliance are critical.
The acquisition builds on Cohere’s growing footprint in Canada and Germany while accelerating its momentum across Europe. By integrating Reliant AI’s technology, Cohere aims to provide healthcare and life sciences organizations with secure deployment options, advanced AI systems, and specialized expertise designed to improve operational efficiency and accelerate innovation.
Aidan Gomez, Co-founder and CEO of Cohere, emphasized the strategic importance of the healthcare sector for AI innovation and highlighted the need for sovereign, secure, and industry-specific systems. The acquisition will also support the expansion of North for Pharma, Cohere’s agentic AI system designed specifically for biopharma workflows across research and development, clinical development, and scientific analytics.
Reliant AI’s flagship platform is an intelligent research workbench used by biopharma companies to automate systematic literature reviews, competitive intelligence gathering, and extraction of scientific and regulatory data. The platform also helps organizations identify therapeutic precedents and evaluate market viability, significantly accelerating decision-making and time-to-market timelines.
Founded in 2023 by Karl Moritz Hermann, Richard Schlegel, and Marc G. Bellemare, Reliant AI has developed specialized AI capabilities for pharmaceutical and biotechnology workflows. Following the acquisition, Karl Moritz Hermann will join Cohere as VP of AI Verticalizations in Berlin, while Marc Bellemare will become VP of Modeling based in Montreal.
Karl Moritz Hermann said the acquisition provides an opportunity to scale Reliant AI’s biopharma AI solutions globally while maintaining the security and sovereignty standards required by life sciences organizations. He added that the combined expertise of the two companies will help accelerate drug discovery and research innovation worldwide.
The acquisition also expands Cohere’s customer relationships in the pharmaceutical sector, including organizations such as GSK, Medicus Pharma, and Kyowa Kirin. Cohere said it will continue advancing Reliant AI’s ongoing engagements with major pharmaceutical companies.
Founded in 2019, Cohere develops enterprise AI foundation models and products focused on security, privacy, and deployment flexibility across cloud, private, and on-premises environments. The company has raised approximately $1.6 billion from investors including NVIDIA, AMD Ventures, Salesforce Ventures, Oracle, and Cisco.
KEY QUOTES:
“We’re excited to welcome the Reliant AI team to Cohere as we deepen our work across healthcare and biopharma. Healthcare represents one of the most consequential opportunities for AI and it demands secure, sovereign, and domain-specific systems. Together, we will accelerate progress in healthcare, building on our shared footprint across Canada and Germany to serve these critical sectors. We look forward to bringing North for Pharma to customers and partners as a cornerstone in our expanding portfolio of industry-specific AI products.”
Aidan Gomez, Co-founder And CEO, Cohere
“Joining Cohere represents a transformative opportunity to scale our biopharma AI solutions globally while maintaining the security and sovereignty that life sciences organizations require. Our combined expertise will accelerate drug discovery and research innovation for customers around the world.”
Karl Moritz Hermann, CEO, Reliant AI
